Costas acquires Atlas Nanotech, a high-tech nanotechnology research and development company focused on the field of nanomedicine. The acquisition is an all-stock transaction of 25m stocks to the principles of Atlas. The terms of the share exchange agreement include the appointment of new managing officers and a new board of directors, the resignation of COSTA’s current officers and board of directors and the retirement of 12.6m shares. Costas’ new board of directors and executive team will include members of Atlas executive board and its key management executives.